Therapeutic Response of Cannabidiol in Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title: Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Cannabidiol (CBD) in Moderate to Severe Rheumatoid Arthritis

Status Completed

Clinical Trial Summary

The study will randomly assign Rheumatoid Arthritis (RA) patients on stable RA therapy to either placebo or cannabidiol (CBD). The overall goal of this proposal is to examine the efficacy and safety of CBD treatment as adjunctive to the medical management of RA patients.

Clinical Trial Description

This is a randomized, placebo-controlled, double-blind clinical trial at the University of California, Los Angeles evaluating the efficacy, safety, and tolerability of oral cannabidiol (CBD) as adjunctive for rheumatoid arthritis (RA) patients on stable therapy. Patients with moderate to severe RA meeting study inclusion criteria will be randomly assigned to one of three treatment groups (CBD 200 mg BID, CBD 400 mg BID, or placebo). Patients in all groups will receive CBD or placebo under observation for 12 weeks with an additional follow-up phone call occurring 4 weeks after. ;

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Cannabis
• Rheumatoid Arthritis

• NCT number: NCT04911127
• Study type: Interventional
• Source: University of California, Los Angeles
• Status: Completed
• Phase: Phase 1
• Start date: October 5, 2021
• Completion date: December 31, 2023